He and the Board would do well to go to school on NAN's US and European rollout and sales strategy plus Regulatory green light ability also....yes NAN has the capital growth and are reinvesting heavily into Trophon2 instead of divis....also a wise move as the consumables sales etc are hitting their stride for the original devices in service plus their competitors products are inferior in cost and more importantly efficacy according to the end users of Trophon ....LBT has that potential but are in a far more competitive sector of the medical game. Anyhoo at least LBT have a sale on the board and St Vinnies too boot.
WTF
He and the Board would do well to go to school on NAN's US and...
-
- There are more pages in this discussion • 72 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
